← Companies|Tessa Therapeutics
Te

Tessa Therapeutics

Singapore SGFounded 2013120 employees
Private CapbiotechPrivateOncology
Platform: Virus-spec T
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
2
FDA Approved
1
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
TES-1600TES-1600Phase 1/22DegraderVEGFIL-13iCKD
TES-326TES-326Approved1mRNATauWRNiHNSCCMeso
TezebrutinibTES-1657Preclinical2VaccineHER2CAR-T BCMALGSAtopic Derm
MirivorutinibTES-7971Phase 2/32NanobodyWRNPLK4iSLEET
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (6)
2025-08-23
Mirivorutinib Ph3 Readout
ET
Past
2026-01-02
Mirivorutinib Ph3 Readout
SLE
Past
2026-03-20
TES-1600 Ph2 Data
CKD
Past
2026-07-19
TES-1600 Enrollment Complete
CKD
Enrollment Complete
2029-10-15
TES-1600 Ph2 Data
CKD
Ph2 Data
2030-12-12
Tezebrutinib Interim
LGS
Interim